

Publications Relating to GDUFA Science and Research in Fiscal Year 2023

1. Al Shoyaib A, Riedmaier A, Kumar A, Roy P, Parrott N, Fang L, Tampal N, Yang Y, Jereb R, Zhao L, and Wu F. *Regulatory Utility of Physiologically Based Pharmacokinetic Modeling for Assessing Food Impact in Bioequivalence Studies: A Workshop Summary Report*. CPT: Pharmacometrics & Systems Pharmacology. (2023) 12(5): 610-618. <https://doi.org/10.1002/psp4.12913>. PMID: 36597353.
2. Amini E, Berger S, Schilling U, Jiao Y, Chen M, Bachhav S, Baumstein S, Tang Y, Al-Humiari M, Astudillo C, Drescher S, Iley T, Shur J, Price R, Carrasco C, Conti D, Delvadia R, Oguntimein O, Witzmann K, Absar M, Luke M, Boc S, Dhapare S, Saluja B, Bielski E, Newman B, Bulitta J, and Hochhaus G. *Sensitivity of Pharmacokinetics to Differences in the Particle Size Distribution for Formulations of Locally Acting Mometasone Furoate Suspension-Based Nasal Sprays*. Molecular Pharmaceutics. (2023) 20: 5690-5700. <https://doi.org/10.1021/acs.molpharmaceut.3c00553>. PMID: 37773975.
3. Babiskin A, Wu F, Mousa Y, Tan M, Tsakalozou E, Walenga R, Yoon M, Raney S, Polli J, Schwendeman A, Krishnan V, Fang L, and Zhao L. *Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches: A Workshop Overview*. CPT: Pharmacometrics & Systems Pharmacology. (2023) 12: 618-623. <https://doi.org/10.1002/psp4.12920>. PMID: 36631942.
4. Babiskin A, Wu F, Mousa Y, Tan M-L, Tsakalozou E, Walenga R, Yoon M, Raney S, Polli J, Schwendeman A, Krishnan V, Fang L, and Zhao L. *Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches: A Workshop Overview*. CPT: Pharmacometrics & Systems Pharmacology. (2023) 12: 619 - 623. <https://doi.org/10.1002/psp4.12920>. PMID: 36631942.
5. Banstola B, Gamage P, Jiang W, and Mudalige T. *Analysis of Phospholipids and Triacylglycerols in Intravenous Lipid Emulsions*. Journal of Pharmaceutical and Biomedical Analysis. (2023) 222: 115112. <https://doi.org/10.1016/j.jpba.2022.115112>. PMID: 36274478.
6. Banstola B, Gamage P, Jiang W, and Mudalige T. *Analysis of Phospholipids and Triacylglycerols in Intravenous Lipid Emulsions*. Journal of Pharmaceutical and Biomedical Analysis. (2023) 222: 115112. <https://doi.org/10.1016/j.jpba.2022.115112>. PMID: 36274478.
7. Bao Q, Fansa S, and Burgess D. *Long-Acting Intrauterine Systems: Recent Advances, Current Challenges, and Future Opportunities*. Advanced Drug Delivery Reviews. 191: 114581. <https://doi.org/10.1016/j.addr.2022.114581>. PMID: 36270490.
8. Bao Q, Wang X, Wan B, Zou Y, Wang Y, and Burgess D. *Development of In Vitro-In Vivo Correlations for Long-Acting Injectable Suspensions*. International Journal of Pharmaceutics. (2023) 634: 122642. <https://doi.org/10.1016/j.ijpharm.2023.122642>. PMID: 36709013.
9. Belenos A, Wood E, Hu M, Kozak D, Xu X, and Fisher A. *Product Quality Research for Developing and Assessing Regulatory Submissions for Generic Cyclosporine Ophthalmic Emulsions*. The AAPS Journal. (2023) 25: 20. <https://doi.org/10.1208/s12248-023-00781-x>. PMID: 36702976.

10. Beringhs A, Naageshwaran V, Gum G, Seremak D, Malla S, Vo A, Tan M-L, Babiskin A, Wang Y, Xu X, and Kozak D. *Impact of Variations in Critical Quality Attributes of Brinzolamide Ophthalmic Suspensions on Preclinical Pharmacokinetics and Pharmacodynamics Following Once-Daily Topical Instillations*. IOVS: Investigative Ophthalmology & Visual Science. (2023) 64(8). <https://iovs.arvojournals.org/article.aspx?articleid=2790564>.
11. Chandrashekar A, Beig A, Wang Y, and Schwendeman S. *In Vitro Performance of Composition-Equivalent PLGA Microspheres Encapsulating Exenatide Acetate by Solvent Evaporation*. International Journal of Pharmaceutics. (2023) 643; 123213. <https://doi.org/10.1016/j.ijpharm.2023.123213>. PMID: 37423376.
12. Chen K, and Smith C. *Best Practices for Submission of NMR Data to Support Higher Order Structure Assessment of Generic Peptide Drugs*. The AAPS Journal. (2023) 25. <https://doi.org/10.1208/s12248-023-00782-w>. PMID: 36670271.
13. Clark A, Wang R, Lomeo J, Wang Y, Zhu A, Shen M, Bao Q, Burgess D, Qin B, and Zhang S. *Investigating Structural Attributes of Drug Encapsulated Microspheres with Quantitative X-ray Imaging*. Journal of Controlled Release. (2023) 358: 626-635. <https://doi.org/10.1016/j.jconrel.2023.05.019>. PMID: 37209962.
14. Costello M, Liu J, Chen B, Wang Y, Qin B, Xu X, Li Q, Lynd N, and Zhang F. *Drug Release Mechanisms of High-Drug-Load, Melt-Extruded Dexamethasone Intravitreal Implants*. European Journal of Pharmaceutics and Biopharmaceutics. (2023) 187: 46-56. <https://doi.org/10.1016/j.ejpb.2023.04.003>. PMID: 37037387.
15. Costello M, Liu J, Wang Y, Bin Q, Xu X, Li Q, Lynd N, and Zhang F. *Reverse Engineering the Ozurdex Dexamethasone Intravitreal Implant*. International Journal of Pharmaceutics. (2023) 634: 122625. <https://doi.org/10.1016/j.ijpharm.2023.122625>. PMID: 36690129.
16. Coutinho A, Cristofolletti R, Wu F, Al Shoyaib A, Dressman J, and Polli J. *A Robust, Viable, and Resource Sparing HPLC-based logP Method Applied to Common Drugs*. International Journal of Pharmaceutics. (2023) 644:123325. <https://doi.org/10.1016/j.ijpharm.2023.123325>. PMID: 37591472.
17. De Groot A, Roberts B, Mattei A, Lalias S, Boyle C, and Martin W. *Immunogenicity Risk Assessment of Synthetic Peptide Drugs and their Impurities*. Drug Discovery Today. (2023) 28(103714). <https://doi.org/10.1016/j.drudis.2023.103714>. PMID: 37467878.
18. Fang L, Li Z, Kinjo M, Lomonaco S, Zheng N, Jiang W, and Zhao L. *Generic Lamotrigine Extended-Release Tablets are Bioequivalent to Innovator Drug in Fully Replicated Crossover Bioequivalence Study*. Epilepsia. (2022) 64(1): 152 - 161. <https://doi.org/10.1111/epi.17438>. PMID: 36259141.
19. Feng X, Wu K, Balajee V, Leissa J, Ashraf M, and Xu X. *Understanding Syringeability and Injectability of High Molecular Weight PEO Solution through Time-Dependent Force-Distance Profiles*. International Journal of Pharmaceutics. (2023) 631: 122486. <https://doi.org/10.1016/j.ijpharm.2022.122486>. PMID: 36521635.
20. German C, Chen Z, Przekwas A, Walenga R, Babiskin A, Liang Z, Fan J, and Tan M. *Computational Model of In Vivo Corneal Pharmacokinetics and Pharmacodynamics of Topically Administered*

Ophthalmic Drug Products. *Pharmaceutical Research*. (2023) 40(4): 961–975.
<https://doi.org/10.1007/s11095-023-03480-6>. PMID: 36959411.

21. Gong Y, Zhang P, Yoon M, Zhu H, Kohojkar A, Hooker A, Ducharme M, Gobburu J, Celliere G, Gajjar P, Li B, Velagapudi R, Tsang Y, Schwendeman A, Poli J, Fang L, Lionberger R, and Zhao L. *Establishing the Suitability of Model-Integrated Evidence to Demonstrate Bioequivalence for Long-Acting Injectable and Implantable Drug Products: Summary of Workshop*. *CPT: Pharmacometrics & Systems Pharmacology*. (2023) 12: 624 - 630. <https://doi.org/10.1002/psp4.12931>. PMID: 36710372.
22. Henry S, Arfvidsson C, Arrington J, Canadi J, Crowe D, Gupta S, Lohmann S, Massonnet B, Mytych D, Rogers T, Rogers H, Stebbins C, Stovold C, Verthelyi D, Vigil A, Chi X, Xu Y, Yu R, and Klem T. *Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs*. *Nucleic Acid Therapeutics*. 32: 369 - 377. <https://doi.org/10.1089/nat.2021.0112>. PMID: 36178478.
23. Hong J, Schutzman R, Olsen K, Chandrashekar A, and Schwendeman S. *Mapping In Vivo Microclimate pH Distribution in Exenatide-Encapsulated PLGA Microspheres*. *J Control Release*. (2023) 352: 438-449.
24. Jani D, Marsden R, Gunsior M, Hay L, Ward B, Cowan K, Azadeh M, Barker B, Cao L, Closson K, Coble K, Dholakiya S, Dusseault J, Hays A, Herl C, Hodson M, Irvin S, Kirshner S, Kolaitis G, Kulagina N, Kumar S, Lai C, Lipari F, Liu S, Merdek K, Moldovan I, Mozaffari R, Pan L, Place C, Snoeck V, Manning M, Stocker D, Tary-Lehmann M, Turner A, Vainshtein I, Verthelyi D, Williams W, Yan H, Yan W, Yang L, Yang L, Zemo J, and Zhong Z. *Anti-drug Antibody Sample Testing and Reporting Harmonization*. *The AAPS Journal*. 24: 113. <https://doi.org/10.1208/s12248-022-00762-6>. PMID: 36307592.
25. Kimbell J, Garcia G, Schroeter J, Sheth P, Vallorz-III E, Saluja B, Babiskin A, Tian G, and Walenga R. *Nasal Steroid Spray Simulations Using Measured Spray Characteristics in Healthy and Rhinitic Nasal Passages*. *Journal of Aerosol Science*. (2023) 174: 106246.
<https://doi.org/10.1016/j.jaerosci.2023.106246>.
26. Kolanjiyil A, Walenga R, Babiskin A, Golshahi L, Hindle M, and Longest W. *Establishing Quantitative Relationships Between Changes in Nasal Spray In Vitro Metrics and Drug Delivery to the Posterior Nasal Region*. *International Journal of Pharmaceutics*. (2023) 635: 122718.
<https://doi.org/10.1016/j.ijpharm.2023.122718>. PMID: 36781083.
27. Kozak D, Zhu D, Zhang Y, Dong Y, Patel D, and Xu X. *Measuring Drug Partitioning and Release to Support In Vitro Bioequivalence of Generic Ophthalmic Emulsion Drugs*. *IOVS: Investigative Ophthalmology & Visual Science*. 64(8): 1143. <https://iovs.arvojournals.org/article.aspx?articleid=2786629>.
28. Kumar V, Wang F, Hu M, Kluetz P, and Liang Z. *Landscape Analysis of Generic Availability for Oncologic Drugs*. *Therapeutic Innovation & Regulatory Science*. (2023) 57(6): 1279-1286.
<https://doi.org/10.1007/s43441-023-00562-w>. PMID: 37561261.
29. Le Merdy M, Alqaraghuli F, Tan M, Walenga R, Babiskin A, Zhao L, and Lukacova V. *Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation*. *Pharmaceutical Research*. (2023) 40: 961-975. <https://doi.org/10.1007/s11095-022-03390-z>. PMID: 36151444.

30. Li X, He X, Le Y, Guo X, Bryant M, Atrakchi A, MCGovern T, Davis Bruno K, Keire D, Heflich R, and Mei N. *Genotoxicity Evaluation of Nitrosamine Impurities using Human TK6 Cells Transduced with Cytochrome P450s*. Archives of Toxicology. (2022) 96(11). <https://doi.org/10.1007/s00204-022-03347-6>. PMID: [35882637](https://pubmed.ncbi.nlm.nih.gov/35882637/).
31. Li X, Le Y, Seo J, Guo X, Li Y, Chen S, Mittelstaedt R, Moore N, Guerrero S, Sims A, King S, Atrakchi A, MCGovern T, Davis Bruno K, Keire D, Elespuru R, Heflich R, and Mei N. *Revisiting the Mutagenicity and Genotoxicity of N-nitroso Propranolol in Bacterial and Human in Vitro Assays*. Regulatory Toxicology and Pharmacology. (2023) 141(105410). <https://doi.org/10.1016/j.yrtph.2023.105410>. PMID: 37210026.
32. Maciel-Tabosa M, Vitry P, Zampini P, Bunge A, Belsey N, Tsikritsis D, Woodman T, Jane White K, Begona Delgado-Charro M, and Guy R. *Quantification of Chemical Uptake into the Skin by Vibrational Spectroscopies and Stratum Corneum Sampling*. Molecular Pharmaceutics. 20(5): 2527-2535. <https://doi.org/10.1021/acs.molpharmaceut.2c01109>. PMID: 37053523.
33. Mekjaruskul C, O'Reilly Beringhs A, Qin B, Wang Y, Chowdhury P, and Lu X. *Impact of Apparatus and Adapter on In Vitro Drug Release of Ophthalmic Semisolid Drug Products*. Pharmaceutical Research. 40: 2239–2251. <https://doi.org/10.1007/s11095-023-03586-x>. PMID: 37679656.
34. Mohan A, Wang Q, Dhapare S, Bielski E, Kaviratna A, Han L, Boc S, and Newman B. *Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development*. Pharmaceutics. 14(11): 2495. <https://doi.org/https://doi.org/10.3390/pharmaceutics14112495>. PMID: 36432683.
35. Naageshwaran V, Bigonne H, Gum G, Malla S, Sol C, Bon C, Xu X, Vo A, Smith W, O'Reilly Beringhs A, Kozak D, Tan M-L, Babiskin A, Babiskin A, Urtti A, Amo E, and Ranta V. *Topical Pharmacokinetics of Brinzolamide Suspensions in Rabbits and Variability Analysis for Sample Size and Design Considerations*. International Journal of Pharmaceutics. (2023) 642(123183). <https://doi.org/10.1016/j.ijpharm.2023.123183>. PMID: 37369289.
36. Nejad H, Zaman R, Smith W, Wu K, Feng X, Beringhs A, Wang Y, Kozak D, and Xu X. *Impact of Material and Manufacturing Process on Performance of an Ophthalmic Implant*. IOVS: Investigative Ophthalmology & Visual Science. (2023) 64(8). <https://iovs.arvojournals.org/article.aspx?articleid=2789641>.
37. Pan L, Mora J, Walravens K, Wagner L, Hopper S, Loo L, Bettoun D, Bond S, Dessy F, Downing S, Garofolo F, Gupta S, Henderson N, Irwin C, Ishii-Watabe A, Kar S, Jawat V, Joseph J, Malvaux L, Marshall J, Mcdevitt J, Mohapatra S, Seitzer J, Smith J, Solstad T, Sugimoto H, Tounekti O, Wu B, We Y, Xu Y, Xu J, Yamamoto T, Yang L, Torri A, Kirshner S, Maxfield K, Pedras Vasconcel J, Rajabi Abhari M, Verthelyi D, Brodsky E, Carrasco-Triguero M, Kamerud J, Andisik M, Baltrukonis D, Bivi N, Cludts I, Coble K, Gorovits B, Gunn G, Gupta S, Holm Milner A, Joyce A, Kubiak R, Kumar S, Liao K, Manangeeswaran M, Partridge M, Pine S, Poetzl J, Rajadhyakshas M, Rasamoelisololo M, Richards S, Song Y, Swanson S, Thacker S, Wadhwa M, Wolf A, Zhang L, and Zhou L. *2022 White Paper on Recent Issues in Bioanalysis: FDA Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, LNP & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, ADA Affinity, Risk-based Approaches, NGS, qPCR, ddPCR Assays (Part 3 - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)*. Bioanalysis. 15(14): 773-814. <https://doi.org/10.4155/bio-2023-0135>. PMID: 37526071.

38. Pawar G, Wu F, Zhao L, Fang L, Burckart G, Feng K, Mousa Y, Al Shoyaib A, Jones M, and Batchelor H. *Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study*. The AAPS Journal. (2023) 25(4). <https://doi.org/10.1208/s12248-023-00826-1>.
39. Pawar G, Wu F, Zhao L, Fang L, Burckart G, Feng K, Mousa Y, Al Shoyaib A, Jones M, and Batchelor H. *Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study*. The AAPS Journal. (2023) 25(4): 67. <https://doi.org/https://doi.org/10.1208/s12248-023-00826-1>. PMID: 37386339.
40. Qu H, Smith W, Feng X, Wang J, Pinto J, Xu X, and Faustino P. *Asymmetrical Flow Field Flow Fractionation for Molar Mass Characterization of Polyethylene Oxide in Abuse-Deterrent Formulations*. Journal of Chromatography. A. (2023) 1705: 464186. <https://doi.org/10.1016/j.chroma.2023.464186>. PMID: 37453175.
41. Rajaraman P, Choi J, Babiskin A, Walenga R, and Lin C. *Transport and Deposition of Beclomethasone Dipropionate Drug Aerosols with Varying Ethanol Concentration in Severe Asthmatic Subjects*. International Journal of Pharmaceutics. (2023) 636: 122805. <https://doi.org/10.1016/j.ijpharm.2023.122805>. PMID: 36898619.
42. Raney S, Senemar S, Burke M, Lee C, Shah J, Li K, Anand O, and Warner K. *Advances in Product Quality and Performance Tests for Topical and Transdermal Products - View of The USP Expert Panel*. United States Pharmacopeia (49-5). Stimuli PF. (2023). https://doi.org/https://doi.org/10.31003/USPNF_S203204_10101_01.
43. Ray S, Boudewyns V, Oguntimein M, Conti D, Malik R, Srivastava I, and Feibus K. *Generic Substitution of Epinephrine Autoinjectors: Patient and Caregiver Perceptions and Attitudes*. Journal of Allergy and Clinical Immunology - Global. 3(1): 100170. <https://doi.org/10.1016/j.jacig.2023.100170>. PMID: 37876855.
44. Ray S, Boudewyns V, Oguntimein O, Conti D, Malik R, Srivastava I, and Feibus K. *Generic Substitution of Epinephrine Autoinjectors: Patient and Caregiver Perceptions and Attitudes*. The Journal of Allergy and Clinical. Global. (2024) 3. <https://doi.org/10.1016/j.jacig.2023.100170>. PMID: 37876855.
45. Schutzman R, Shi N, Olsen K, Ackermann R, Tang J, Liu Y, Hong J, Wang Y, Qin B, Schwendeman A, and Schwendeman S. *Mechanistic Evaluation of the Initial Burst Release of Leuprolide from Spray-Dried PLGA Microspheres*. Journal of Controlled Release. (2023) 361: 297-313. <https://doi.org/10.1016/j.jconrel.2023.06.016>. PMID: 37343723.
46. Senemar S, Kuzma B, Ramezanli T, Ghosh P, Raney S, Rantou E, and Stagni G. *Bioequivalence Evaluation of Topical Metronidazole Products Using Dermal Microdialysis in New Zealand Rabbits*. AAPS PharmSciTech. 24(7): 204. <https://doi.org/10.1208/s12249-023-02660-2>. PMID: 37789133.
47. Shakleya D, Asmelash B, Alayoubi A, Abrigo N, Mohammad A, Wang J, Zhang J, Yang J, Marzan T, Li D, Shaklah M, Alsharif F, Desai S, Faustino P, Muhammad A, O'connor T, Vera M, Raw A, Sayeed V, and Keire D. *Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets*. Journal of Pharmaceutical Sciences. (2023) S0022-3549(23): 00244-7. <https://doi.org/10.1016/j.xphs.2023.06.013>. PMID: 37364772.

48. Shi Y, Ren P, Wang J, Han B, Valizadehaslani T, Agbavor F, Zhang Y, Hu M, Zhao L, and Liang H. *Leveraging GPT-4 for Food Effect Summarization to Enhance Product-Specific Guidance Development via Iterative Prompting*. ArXiv:2207.12376. (2023) <https://doi.org/10.48550/arXiv.2306.16275>.
49. Shi Y, Wang J, Ren P, Valizadehaslani T, Zhang Y, Hu M, and Liang H. *Fine-Tuning Bert for Automatic ADME Semantic Labeling in FDA Drug Labeling to Enhance Product-Specific Guidance Assessment*. *Journal of Biomedical Informatics*. 138: 104285. <https://doi.org/10.1016/j.jbi.2023.104285>. PMID: 36632860.
50. Simon C, Borgos S, Calzolari L, Nelson B, Parot J, Petersen E, Roesslein M, Xu X, and Caputo F. *Orthogonal and Complementary Measurements of Properties of Drug Products Containing Nanomaterials*. *Journal of Controlled Release*. 354: 120-127. <https://doi.org/10.1016/j.jconrel.2022.12.049>. PMID: 36581261.
51. Smith W, Qu H, Zheng K, Baek J, Gao Y, Buehler P, Feng X, and Xu X. *Determining Critical Overlap Concentration of Polyethylene Oxide to Support Excipient Safety Assessment of Opioid Products*. *International Journal of Pharmaceutics*. (2023) 632: 122557. <https://doi.org/10.1016/j.ijpharm.2022.122557>. PMID: 36584863.
52. Szapacs M, Jian W, Spellman D, Cunliffe J, Verburg E, Kaur S, Kelliet J, Li W, Mehl J, Qian M, Qiu X, Sirtori F, Rosenbaum A, Sikorski T, Surapaneni S, Wang J, Wilson A, Zhang J, Xue Y, Post N, Huang Y, Goykhman D, Yuan L, Fang K, Casavant E, Chen L, Fu Y, Huang M, Ji A, Johnson J, Lassman M, Li J, Saad O, Sarvaiya H, Tao L, Wang Y, Zheng N, Dasgupta A, Rajabi Abhari M, Ishii-Watabe A, Saito Y, Fernandez A, Fernandes D, Bower J, Burns C, Carleton K, Cho S, Du X, Fjording M, Garofolo F, Kar S, Kavetska O, Kossary E, Lu Y, Mayer A, Palackal N, Saiha D, Thomas E, Verhaeghe T, Vinter S, Wan K, Wang Y, Williams K, Woolf E, Yang E, Bandukwala A, Hopper S, Maher K, Xu J, Brodsky E, Cludts I, Irwin C, Joseph J, Kirshner S, Manangeeswaran M, Maxfield K, Pedras Vasconcel J, Solstad T, Thacker S, Tounekti O, Verthelyi D, Wadhwat M, Wagner L, Yamamoto T, Zhang L, and Zhou L. *2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A - Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline Global Harmonization Part 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene Cell Therapy and Vaccine)*. *Bioanalysis*. (2023) 15: 955-1016. <https://doi.org/https://doi.org/10.4155/bio-2023-0167>. PMID: [37650500](https://pubmed.ncbi.nlm.nih.gov/37650500/).
53. Tan M-L, Chandran S, Jereb R, Alam K, Bies R, Kozak D, Walenga R, Le Merdy M, and Babiskin A. *Mechanistic Modeling of Ophthalmic, Nasal, Injectable, and Implant Generic Drug Products: a Workshop Summary Report*. *CPT: Pharmacometrics & Systems Pharmacology*. (2023) 12(5): 631–638. <https://doi.org/10.1002/psp4.12952>. PMID: 36851886.
54. Tang P, Kakhi M, Albariqi A, Behara S, Walenga R, Yang R, and Chan H. *The Role of Capsule Aperture Size on the Dispersion of Carrier-based Formulation at Different Air Flowrates*. *International Journal of Pharmaceutics*. (2023) 642(123152). <https://doi.org/10.1016/j.ijpharm.2023.123152>. PMID: 37339687.
55. Tardivon C, Loingeville F, Donnelly M, Feng K, Sun W, Sun G, Grosser S, Zhao L, Fang L, Mentre F, and Bertrand J. *Evaluation of Model - Based Bioequivalence Approach for Single Pharmacokinetic*

- Studies*. CPT: Pharmacometrics & Systems Pharmacology. (2023) 2(7):904-915. <https://doi.org/10.1002/psp4.12960>. PMID: 37114321.
56. Tardivon C, Loingeville F, Donnelly M, Feng K, Sun W, Sun G, Grosser S, Zhao L, Fang L, Mentre F, and Bertrand J. *Evaluation of Model-based Bioequivalence Approach for Single Sample Pharmacokinetic Studies*. CPT: Pharmacometrics & Systems Pharmacology. (2023) 12(7): 904-915. <https://doi.org/10.1002/psp4.12960>. PMID: 37114321.
57. Thomas S, Hammell D, Hassan H, and Stinchcomb A. *In Vitro-In Vivo Correlation of Buprenorphine Transdermal Systems Under Normal and Elevated Skin Temperature*. *Pharmaceutical Research*. (2023) 40(5): 1249 – 1258. <https://doi.org/10.1007/s11095-023-03487-z>. PMID: 37095369.
58. Tsakalozou E, Alam K, Ghosh P, Spires J, Polak S, Fang L, Sammeta S, Zhao P, Arora S, and Raney S. *Mechanistic Modeling of Drug Products Applied to the Skin: A Workshop Summary Report*. CPT: Pharmacometrics & Systems Pharmacology. (2022) 12: 575 - 584. <https://doi.org/10.1002/psp4.12893>. PMID: 36456539.
59. Valizadehaslani T, Shi Y, Ren P, Wang J, Zhang Y, Hu M, Zhao L, and Liang H. *PharmBERT: A Domain-specific BERT Model for Drug Labels*. *Briefings in Bioinformatics*. (2023) 24(4). <https://doi.org/10.1093/bib/bbad226>. PMID: [37317617](https://pubmed.ncbi.nlm.nih.gov/37317617/).
60. Walenga R, Butler C, Craven B, Longest W, Mohamed R, Newman B, Olsson B, Hochhaus G, Li B, Luke M, Zhao L, Przekwas A, and Lionberger R. *Mechanistic Modeling of Generic Orally Inhaled Drug Products (OIDPs): A Workshop Summary Report*. CPT Pharmacometrics & Systems and Pharmacology. (2022) 12: 560 - 574. <https://doi.org/10.1002/psp4.12889>. PMID: 36330693.
61. Wang D, Su Y, and Chen K. *Fast Dynamics of Difluprednate in Micelles or Swollen-Micelles Revealed by ¹⁹F Nuclear Magnetic Resonance Spin Relaxation Rates*. *The Journal of Physical Chemistry Letters*. (2023) 14: 4837-4841. <https://doi.org/10.1021/acs.jpcllett.3c00846>. PMID: 37193655.
62. Wang K, and Chen K. *Direct Assessment of Oligomerization of Chemically Modified Peptides and Proteins in Formulations using DLS and DOSY-NMR*. *Pharmaceutical Research*. (2023) 40(6): 1329-1339. <https://doi.org/10.1007/s11095-022-03468-8>. PMID: 36627448.
63. Wang K, Dai W, Qian K, Scott B, and Chen K. *A Precise qNMR Method for the Rapid Quantification of Lot-to-Lot Variations in Multiple Quality Attributes of Pentosan Polysulfate Sodium*. *The AAPS Journal*. (2023) 25. <https://doi.org/10.1208/s12248-023-00815-4>.
64. Wang R, Bao Q, Clark A, Wang Y, Zhang S, and Burges D. *Characterization and In Vitro Release of Minocycline Hydrochloride Microspheres Prepared via Coacervation*. *International Journal of Pharmaceutics*. (2022) 628(122292). <https://doi.org/10.1016/j.ijpharm.2022.122292>. PMID: [36252639](https://pubmed.ncbi.nlm.nih.gov/36252639/).
65. Wang R, Bao Q, Clark A, Wang Y, Zhang S, and Burgess D. *Characterization and In Vitro Release of Minocycline Hydrochloride Microspheres Prepared via Coacervation*. *International Journal of Pharmaceutics*. (2022) 628: 122292. <https://doi.org/10.1016/j.ijpharm.2022.122292>. PMID: 36252639.
66. Wang X, Bao Q, Wang R, Kwok O, Maurus K, Wang Y, Qin B, and Burgess D. *In Situ Forming Risperidone Implants: Effect of PLGA Attributes on Product Performance*. *Journal of Controlled Release*. (2023) 361: 777-791. <https://doi.org/10.1016/j.jconrel.2023.08.029>. PMID: 37591464.

67. Wang X, Bao Q, Wang R, Li T, Wang Y, Qin B, Li Q, and Burgess D. *In Vivo Characterization of Perseris and Compositionally Equivalent Formulations*. International Journal of Pharmaceutics. (2023) 642: 123170. <https://doi.org/10.1016/j.ijpharm.2023.123170>. PMID: 37354927.
68. Wang X, Bao Q, Wang R, Wan B, Wang Y, and Qin B. *Reverse Engineering of Perseris and Development of Compositionally Equivalent Formulations*. International Journal of Pharmaceutics. (2023) 639: 122948. <https://doi.org/10.1016/j.ijpharm.2023.122948>. PMID: 37044228.
69. Wu F, Mousa Y, Raines K, Bode C, Tsang Y, Cristofolletti R, Zhang H, Heimbach T, Fang L, Kesisoglou F, Mitra A, Polli J, Kim M, Fan J, Zolnik B, Sun D, Zhang Y, and Zhao L. *Regulatory Utility of Physiologically Based Pharmacokinetic Modeling to Support Alternative Bioequivalence Approaches and Risk Assessment: A Workshop Summary Report*. CPT: Pharmacometrics & Systems Pharmacology. (2023) 12(5): 585-597. <https://doi.org/10.1002/psp4.12907>. PMID: 36530026.
70. Wu K, Zheng K, Tian L, Xia L, Hwang S, Nwakama P, Sun W, Kim M, Tampal N, Xu X, Boyce H, and Feng X. *The Effect of Food Vehicles on In Vitro Performance of Pantoprazole Sodium Delayed Release Sprinkle Formulation*. International Journal of Pharmaceutics. (2023) 635: 122737. <https://doi.org/10.1016/j.ijpharm.2023.122737>. PMID: 36801362.
71. Yang J, Kakarla R, Marzan T, Sherwin T, George M, Bennett J, Basutto J, Su Y, Ollerenshaw J, Morin J, Rebiere H, Maggio A, Kermaidic A, Gervela E, Breniew C, Civade C, Chauvey D, Duperray F, Wollein U, Conti M, Tromp J, Meyer S, Wanko R, Wierer M, Bertrand M, Rodriguez J, Sommers C, and Keire D. *Performance Characteristics of Mass Spectrometry-Based Analytical Procedures for Quantitation of Nitrosamines in Pharmaceuticals: Insights from an Inter-laboratory Study*. Journal of Pharmaceutical Sciences. 112(10): 2685–2695. <https://doi.org/10.1016/j.xphs.2023.07.022>. PMID: 37524228.
72. Yilmaz H, Ahmed S, Rodriguez J, and Willett D. *Scanning Electron-Raman Cryomicroscopy for Characterization of Nanoparticle-Albumin Drug Products*. Analytical Chemistry. (2023) 95(5): 2633-2638. <https://doi.org/10.1021/acs.analchem.2c03826>. PMID: 36693238.
73. Yoon M, Babiskin A, Hu M, Wu F, Raney S, Fang L, and Zhao L. *Increasing Impact of Quantitative Methods and Modeling in Establishment of Bioequivalence and Characterization of Drug Delivery*. CPT: Pharmacometrics & Systems Pharmacology. (2023) 12(5): 552 - 555. <https://doi.org/10.1002/psp4.12930>. PMID: 36756902.
74. Yu M, Yuan W, Xia Z, Liu Y, Wang Y, Xu X, Zheng J, and Schwendeman A. *Characterization of Exparel Bupivacaine Multivesicular Liposomes*. International Journal of Pharmaceutics. (2023) 639: 122952. <https://doi.org/10.1016/j.ijpharm.2023.122952>. PMID: 37054926.
75. Zarnpi P, Maciel-Tabosa M, Vitry P, Bunge A, Belsey N, Tsikritsis D, Woodman T, Delgado-Charro M, and Guy R. *Confocal Raman Spectroscopic Characterization of Dermatopharmacokinetics Ex Vivo*. Molecular Pharmaceutics. 20(11): 5910-5920. <https://doi.org/10.1021/acs.molpharmaceut.3c00755>. PMID: 37801410.
76. Zhou J, Schutzman R, Shi N, Ackermann R, Olsen K, Wang Y, and Schwendeman S. *Influence of Encapsulation Variables on Formation of Leuprolide-Loaded PLGA Microsphere*. Journal of Colloid and Interface Science. (2023) 636: 401-412. <https://doi.org/10.1016/j.jcis.2022.11.122>. PMID: 36640551.

